Unknown

Dataset Information

0

Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial.

ABSTRACT: Thiazolidinedione ligands for the gamma subtype of peroxisome proliferator-activated receptors (PPARgamma), widely used to treat type 2 diabetes mellitus, have been proposed as novel therapies for ulcerative colitis (UC).This multicenter, randomized, double-blind, placebo-controlled clinical trial compared the efficacy of rosiglitazone (Avandia; GlaxoSmithKline, Philadelphia, PA) 4 mg orally twice daily vs placebo twice daily for 12 weeks in 105 patients with mild to moderately active UC. Disease activity was measured with the Mayo score. The primary end point was clinical response (>/=2-point reduction) at week 12. Clinical remission (Mayo score

SUBMITTER: Lewis JD 

PROVIDER: S-EPMC2276587 | biostudies-literature | 2008 Mar

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

<h4>Background & aims</h4>Thiazolidinedione ligands for the gamma subtype of peroxisome proliferator-activated receptors (PPARgamma), widely used to treat type 2 diabetes mellitus, have been proposed as novel therapies for ulcerative colitis (UC).<h4>Methods</h4>This multicenter, randomized, double-blind, placebo-controlled clinical trial compared the efficacy of rosiglitazone (Avandia; GlaxoSmithKline, Philadelphia, PA) 4 mg orally twice daily vs placebo twice daily for 12 weeks in 105 patients  ...[more]

Similar Datasets

Unknown Ginger in patients with active ulcerative colitis: a study protocol for a randomized controlled trial.
| S-EPMC7079449 | biostudies-literature
Unknown Adrenomedullin for steroid-resistant ulcerative colitis: a randomized, double-blind, placebo-controlled phase-2a clinical trial.
| S-EPMC7862507 | biostudies-literature
Unknown Remote ischemic conditioning in active ulcerative colitis: An explorative randomized clinical trial.
| S-EPMC7293253 | biostudies-literature
Unknown A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis.
| S-EPMC8365785 | biostudies-literature
Unknown Comprehensive Lifestyle-Modification in Patients with Ulcerative Colitis-A Randomized Controlled Trial.
| S-EPMC7599849 | biostudies-literature
Unknown Chinese herbal extract granules combined with 5-aminosalicylic acid for patients with moderately active ulcerative colitis: study protocol for a multicenter randomized double-blind placebo-controlled trial.
| S-EPMC7805063 | biostudies-literature
Unknown Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis.
| S-EPMC4755132 | biostudies-literature
Unknown First multicenter study of modified release phosphatidylcholine "LT-02" in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses.
| S-EPMC4085478 | biostudies-literature
Unknown Fecal Microbial Transplantation versus Mesalamine Enema for Treatment of Active Left-Sided Ulcerative Colitis-Results of a Randomized Controlled Trial.
| S-EPMC8268406 | biostudies-literature
Unknown Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study.
| S-EPMC6391030 | biostudies-literature